Why the study?
Does exercise-induced sympathetic nervous system activation correlate with circulating FABP4 concentrations in healthy volunteers?
Does exercise-induced sympathetic nervous system activation correlate with circulating FABP4 concentrations in healthy volunteers?
Circulating FABP4 levels correlate significantly with norepinephrine during exercise, suggesting FABP4 may serve as a potential biomarker for adrenergic overdrive.
Suggests FABP4 may serve as a biomarker for adrenergic overdrive; leaves open whether this.
BACKGROUND: Lipolysis is stimulated by activation of adrenergic inputs to adipose tissues. Our recent study showed that serum concentrations of fatty acid binding protein 4 (FABP4) are robustly elevated in patients with acute myocardial infarction and ventricular tachyarrhythmia, that display a marked activation of the sympathetic nervous system (SNS). However, it remains unknown whether circulating FABP4 concentrations are associated with exercise-induced SNS activation. METHODS: Thirty one healthy volunteers underwent cardiopulmonary exercise testing on a cycle ergometer up to the workload levels below and above anaerobic threshold, low- and high-intensity exercise, respectively. Serial blood samplings were performed before and after exercise. RESULTS: High-intensity exercise significantly increased serum concentrations of FABP4 and catecholamines, and their concentrations declined fast thereafter in a similar fashion. These changes were accompanied by little, if any, changes in other metabolic markers. Regardless of adiposity, percent change from baseline to peak FABP4 levels (%FABP4) was comparable in all subjects. Stepwise regression analysis revealed that %FABP4 was highly correlated with that in norepinephrine. CONCLUSIONS: Our study reveals the significant correlation between circulating FABP4 and norepinephrine levels during exercise testing. Together with the fact that FABP4 is secreted from adipocytes via β-adrenergic-mediated lipolytic mechanisms, this study suggests FABP4 as a potential biomarker for adrenergic overdrive.
No takes yet. Share an insight, caveat, or question.
Iso et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: